Treatment of acute (Adult) respiratory distress syndrome. The holy grail of surfactant therapy.
The treatment of neonatal respiratory distress syndrome with surfactant represents a successful culmination of decades of basic and clinical research. In many babies, respiratory distress syndrome is a relatively pure expression of surfactant deficiency. Acute respiratory distress syndrome (ARDS) is a more common disease that is most frequently seen in adults, but the processes are common to lung injuries in newborns and children as well. While some impairment of production and secretion of surfactant constituents may be present in ARDS, surfactant inactivation is probably a more important factor in this disease. Until recently, surfactants available for human use have been easily susceptible to inactivation and this may explain why they have been less successful for treatment of ARDS than for neonatal respiratory distress syndrome. This review outlines recent information on surfactant inactivation and describes initiatives that may result in 'inactivation-proof' surfactants that may be of increased benefit in ARDS.
Taeusch
H W
HW
Department of Pediatrics, University of California, San Francisco, Calif. 94114, USA. btaeusch@sfghpeds.ucsf.edu
D000208:Acute Disease; D000328:Adult; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy; D011663:Pulmonary Surfactants / Q000502:physiology / Q000627:therapeutic use*; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000503:physiopathology
D011663:Pulmonary Surfactants